Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...

A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on ...

Sarepta Therapeutics Inc. plummeted in early trading after reporting a second patient died of acute liver failure while being ...

Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

By Christy Santhosh and Bhanvi Satija (Reuters) -Shares of Sarepta Therapeutics slumped 36% in premarket trading on Monday after the company reported the death of a second patient in three months who ...